Cargando…
Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
AIMS: The Medical Research Council OVO5/EORTC 55955 trial showed that patients in remission after first-line therapy for ovarian cancer did not benefit from routine measurement of CA125 during follow-up. Since the presentation of these results, we have counseled patients about the options for follow...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499967/ https://www.ncbi.nlm.nih.gov/pubmed/28333841 http://dx.doi.org/10.1097/IGC.0000000000000956 |